Categories
Change Password!
Reset Password!
Orlistat shows significant therapeutic benefits in obese diabetic patients, effectively relieving constipation, improving postprandial glucose control, and supporting overall metabolic health.
Obesity represents a significant global health challenge, and has been studied for its potential to boost gastrointestinal function and glycemic control in diabetic patients. This randomized controlled trial explored the influence of orlistat (lipase inhibitor) on 80 overweight diabetic individuals experiencing constipation.
Volunteers were randomly assigned to receive either 120 mg orlistat with lunch or a placebo daily for 3 months. Clinical and laboratory assessments, including body mass index, constipation severity, fasting blood sugar, postprandial glucose, glycated hemoglobin (HbA1C), triglycerides, cholesterol, high-density lipoprotein, creatinine, aspartate transaminase (AST), alanine transaminase (ALT), and blood sugar two hours postprandial (BS-2HPP), were conducted at baseline and following the intervention to evaluate treatment outcomes.
Results revealed that patients in the Orlistat group experienced a significant reduction in postprandial blood sugar (BS-2HPP) and ALT levels compared to the placebo group. Importantly, there was a marked improvement in constipation symptoms among those receiving Orlistat, indicating its potential dual benefit in metabolic and gastrointestinal regulation.
While Orlistat’s effects on other metabolic parameters—such as fasting glucose, HbA1C, and lipid profile—did not reach statistical significance, no adverse side effects were reported throughout the study period. The findings suggest that orlistat can be a beneficial adjunct therapy for diabetic patients struggling with obesity and constipation, helping to improve bowel regularity and postprandial glucose levels without causing side effects.
Iranian Journal of Diabetes and Obesity
The Impact of Orlistat on Diabetic Patients Experiencing Overweight and Constipation: A Randomized Clinical Trial
Mohsen Zabihi et al.
Comments (0)